Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

40.0%

6 terminated/withdrawn out of 15 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

73%

11 trials in Phase 3/4

Results Transparency

78%

7 of 9 completed trials have results

Key Signals

7 with results6 withdrawn

Enrollment Performance

Analytics

Phase 3

9(60.0%)

Phase 2

3(20.0%)

Phase 4

2(13.3%)

N/A

1(6.7%)

15Total

Phase 3(9)

Phase 2(3)

Phase 4(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT02147353Not ApplicableCompleted

Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment

Role: collaborator

NCT02886702Phase 3Completed

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Role: lead

NCT02886715Phase 3Completed

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Role: lead

NCT00746434Phase 2Withdrawn

A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis

Role: collaborator

NCT00746382Phase 2Withdrawn

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

Role: collaborator

NCT01137032Phase 4Completed

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Role: lead

NCT01139450Phase 3Completed

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

Role: lead

NCT01053247Phase 3Completed

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

Role: lead

NCT00546000Phase 4Completed

Cutivate Lotion HPA Axis Pediatric Study

Role: lead

NCT01016782Phase 3Completed

Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea

Role: lead

NCT02176577Phase 3Withdrawn

Study to Determine the Pharmacokinetics of Product 0405

Role: lead

NCT02176551Phase 3Withdrawn

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Role: lead

NCT02176538Phase 3Withdrawn

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Role: lead

NCT00747032Phase 3Withdrawn

To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis

Role: lead

NCT01232543Phase 2Completed

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

Role: lead

All 15 trials loaded